Logo

Merck Collaborates with Instituto Butantan to Develop Vaccines for Dengue

Share this

Merck Collaborates with Instituto Butantan to Develop Vaccines for Dengue

Shots:

  • Instituto Butantan to receive $26M upfront- $75M milestones and royalties on sales from Merck. Merck to get clinical data and learnings (utilized for its TV003- dengue vaccine) from Instituto’s development programs to develop vaccines for dengue
  • The focus of the agreement is to develop live attenuated tetravalent vaccines (LATV) against the dengue virus for patients suffering in Brazil
  • TV003 is a LATV P-III candidate- assessing 17-000 healthy people aged 2 to 59 years in 15 cities- indicated to treat dengue infection

Ref: Merck | Image: Merck


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions